Legal Proceedings
−Removed: From time to time, in the ordinary course of business, the Company is subject to litigation and regulatory examinations as well as information gathering requests, inquiries and investigations.
−Removed: We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us that we believe could have a material adverse effect on our business, operating results, cash flows or financial condition.
+Added: From time to time, we may be subject to litigation and claims arising in the ordinary course of business.
+Added: Such matters are subject to uncertainty and there can be no assurance that such legal proceedings will not have a material adverse effect on our business, results of operations, financial position or cash flows.
+Added: Please see the matter noted below and within Note 12, "Commitments and Contingencies," to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K.
+Added: Excluding the matter noted therein, we are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us that we believe could have a material adverse effect on our business, operating results, cash flows or financial condition.
+Added: Shareholder Complaint
+Added: On July 14, 2025, a lawsuit was filed in the United States District Court for the District of Connecticut against Biohaven Ltd.
+Added: and certain of our officers alleging federal securities law violations on behalf of a putative class of purchasers of our stock between March 24, 2023 and May 14, 2025.
+Added: cc The complaint alleges that Biohaven and the officer defendants violated Section 10(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Rule 10b-5 based on alleged misstatements or omissions in certain Biohaven press releases and SEC filings concerning, among other things, (i) the outlook for and clinical data supporting troriluzole as a treatment for SCA spinocerebellar ataxia and (ii) opakalim’s efficacy and clinical prospects as a treatment for bipolar disorder.
+Added: Plaintiffs also claim the
+Added: individual defendants are liable for the alleged securities violations through derivative “control person” claims under Section 20(a) of the Exchange Act.
+Added: The defendants have not yet answered or otherwise responded to the complaint.
Mine Safety Disclosures
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.